Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24.

Kawai S, Koishihara Y, Iida S, Ozaki S, Matsumoto T, Kosaka M, Yamada-Okabe H.

Leuk Res. 2006 Aug;30(8):949-56. Epub 2006 Feb 13.

PMID:
16473407
2.

Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models.

Kawai S, Yoshimura Y, Iida S, Kinoshita Y, Koishihara Y, Ozaki S, Matsumoto T, Kosaka M, Yamada-Okabe H.

Oncol Rep. 2006 Feb;15(2):361-7.

PMID:
16391855
3.

Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.

Rew SB, Peggs K, Sanjuan I, Pizzey AR, Koishihara Y, Kawai S, Kosaka M, Ozaki S, Chain B, Yong KL.

Clin Cancer Res. 2005 May 1;11(9):3377-84.

4.

Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro.

Hirata T, Shimazaki C, Sumikuma T, Ashihara E, Goto H, Inaba T, Koishihara Y, Nakagawa M.

Leuk Res. 2003 Apr;27(4):343-9.

PMID:
12531226
5.

The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity.

Ono K, Ohtomo T, Yoshida K, Yoshimura Y, Kawai S, Koishihara Y, Ozaki S, Kosaka M, Tsuchiya M.

Mol Immunol. 1999 Apr;36(6):387-95.

PMID:
10444002
6.

Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells.

Ozaki S, Kosaka M, Wakahara Y, Ozaki Y, Tsuchiya M, Koishihara Y, Goto T, Matsumoto T.

Blood. 1999 Jun 1;93(11):3922-30.

PMID:
10339501
7.

Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells.

Ohtomo T, Sugamata Y, Ozaki Y, Ono K, Yoshimura Y, Kawai S, Koishihara Y, Ozaki S, Kosaka M, Hirano T, Tsuchiya M.

Biochem Biophys Res Commun. 1999 May 19;258(3):583-91.

PMID:
10329429
8.

Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24.

Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T.

Blood. 1997 Oct 15;90(8):3179-86.

PMID:
9376601
9.

New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor.

Tsunenari T, Koishihara Y, Nakamura A, Moriya M, Ohkawa H, Goto H, Shimazaki C, Nakagawa M, Ohsugi Y, Kishimoto T, Akamatsu K.

Blood. 1997 Sep 15;90(6):2437-44.

PMID:
9310495
10.

Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation.

Tai H, Miyaura C, Pilbeam CC, Tamura T, Ohsugi Y, Koishihara Y, Kubodera N, Kawaguchi H, Raisz LG, Suda T.

Endocrinology. 1997 Jun;138(6):2372-9.

PMID:
9165025
11.

The influence of interleukin-6 on the growth of human esophageal cancer cell lines.

Oka M, Iizuka N, Yamamoto K, Gondo T, Abe T, Hazama S, Akitomi Y, Koishihara Y, Ohsugi Y, Ooba Y, Ishihara T, Suzuki T.

J Interferon Cytokine Res. 1996 Dec;16(12):1001-6.

PMID:
8974001
12.

Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma.

Tsunenari T, Akamatsu K, Kaiho S, Sato K, Tsuchiya M, Koishihara Y, Kishimoto T, Ohsugi Y.

Anticancer Res. 1996 Sep-Oct;16(5A):2537-44.

PMID:
8917348
13.

Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.

Taetle R, Dos Santos B, Akamatsu K, Koishihara Y, Ohsugi Y.

Clin Cancer Res. 1996 Feb;2(2):253-9.

14.

Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region.

Sato K, Ohtomo T, Hirata Y, Saito H, Matsuura T, Akimoto T, Akamatsu K, Koishihara Y, Ohsugi Y, Tsuchiya M.

Hum Antibodies Hybridomas. 1996;7(4):175-83.

PMID:
9140729
15.
16.

Endogenous bone-resorbing factors in estrogen deficiency: cooperative effects of IL-1 and IL-6.

Miyaura C, Kusano K, Masuzawa T, Chaki O, Onoe Y, Aoyagi M, Sasaki T, Tamura T, Koishihara Y, Ohsugi Y, et al.

J Bone Miner Res. 1995 Sep;10(9):1365-73.

PMID:
7502709
17.

Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism.

Goto H, Shimazaki C, Tatsumi T, Yamagata N, Fujita N, Tsuchiya M, Koishihara Y, Ohsugi Y, Nakagawa M.

Leukemia. 1995 Apr;9(4):711-8.

PMID:
7723407
18.
19.

Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro.

Goto H, Shimazaki C, Tatsumi T, Yamagata N, Hirata T, Ashihara E, Oku N, Inaba T, Fujita N, Koishihara Y, et al.

Jpn J Cancer Res. 1994 Sep;85(9):958-65.

20.

Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions.

Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM.

Mol Immunol. 1994 Apr;31(5):371-81.

PMID:
8152440
21.

Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma.

Taetle R, Dos Santos B, Ohsugi Y, Koishihara Y, Yamada Y, Messner H, Dalton W.

J Natl Cancer Inst. 1994 Mar 16;86(6):450-5.

PMID:
8120920
22.

IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis.

Suzuki H, Takemura H, Yoshizaki K, Koishihara Y, Ohsugi Y, Okano A, Akiyama Y, Tojo T, Kishimoto T, Kashiwagi H.

J Immunol. 1994 Jan 15;152(2):935-42.

PMID:
8283060
23.

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.

Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, et al.

Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11924-8.

24.

Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.

Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T, Kishimoto T.

Blood. 1993 Aug 15;82(4):1120-6.

PMID:
8353278
25.

Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice.

Ohe Y, Podack ER, Olsen KJ, Miyahara Y, Miura K, Saito H, Koishihara Y, Ohsugi Y, Ohira T, Nishio K, et al.

Br J Cancer. 1993 May;67(5):939-44.

26.

Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.

Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM.

Cancer Res. 1993 Feb 15;53(4):851-6.

27.
28.

Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA.

Okuno Y, Takahashi T, Suzuki A, Fukumoto M, Nakamura K, Fukui H, Koishihara Y, Ohsugi Y, Imura H.

Exp Hematol. 1992 May;20(4):395-400.

PMID:
1568457
29.

Interleukin 6 inhibits delayed-type hypersensitivity and the development of adjuvant arthritis.

Mihara M, Ikuta M, Koishihara Y, Ohsugi Y.

Eur J Immunol. 1991 Oct;21(10):2327-31.

PMID:
1915548
30.
31.

Preparation of soluble murine IL-6 receptor and anti-murine IL-6 receptor antibodies.

Saito T, Yasukawa K, Suzuki H, Futatsugi K, Fukunaga T, Yokomizo C, Koishihara Y, Fukui H, Ohsugi Y, Yawata H, et al.

J Immunol. 1991 Jul 1;147(1):168-73.

PMID:
2051018
32.

Estimation of interleukin 6 production by reverse transcriptase-polymerase chain reaction in four human myeloma cell lines.

Suzuki A, Takahashi T, Okuno Y, Fukumoto M, Fukui H, Koishihara Y, Ohsugi Y, Ohno Y, Imura H.

Leuk Res. 1991;15(11):1043-50.

PMID:
1720489
33.

Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6.

Mihara M, Fukui H, Koishihara Y, Saito M, Ohsugi Y.

Clin Exp Immunol. 1990 Dec;82(3):533-7.

34.

Purification and characterization of soluble human IL-6 receptor expressed in CHO cells.

Yasukawa K, Saito T, Fukunaga T, Sekimori Y, Koishihara Y, Fukui H, Ohsugi Y, Matsuda T, Yawata H, Hirano T, et al.

J Biochem. 1990 Oct;108(4):673-6.

35.

Human urinary erythropoietin: preparation with high potency.

Matsushita J, Kawakita M, Shibuya K, Koishihara Y, Sakaguchi M, Takatsuki A.

Acta Haematol. 1990;84(4):169-74.

PMID:
2125780
36.

Production of interleukin 6 by human spleen cells stimulated with streptococcal preparation OK-432.

Fukui H, Koishihara Y, Nagamuta M, Mizutani Y, Uchida A.

Immunol Lett. 1989 May;21(2):127-30.

PMID:
2788613
37.

The effects of human erythropoietin on murine megakaryopoiesis.

Kawakita M, Sakaguchi M, Matsushita J, Shibuya K, Koishihara Y, Takatsuki K.

Nihon Ketsueki Gakkai Zasshi. 1987 Dec;50(8):1586-95. No abstract available.

PMID:
3502309
38.

Human erythropoietin stimulates murine megakaryopoiesis in serum-free culture.

Sakaguchi M, Kawakita M, Matsushita J, Shibuya K, Koishihara Y, Takatsuki K.

Exp Hematol. 1987 Nov;15(10):1028-34.

PMID:
3499335
39.

The expression of functional erythropoietin receptors on an interleukin-3 dependent cell line.

Sakaguchi M, Koishihara Y, Tsuda H, Fujimoto K, Shibuya K, Kawakita M, Takatsuki K.

Biochem Biophys Res Commun. 1987 Jul 15;146(1):7-12.

PMID:
3038112
40.

Human urinary megakaryocyte colony- and thrombopoiesis-stimulating factor.

Kawakita M, Sakaguchi M, Matsushita J, Shibuya K, Koishihara Y, Takatsuki K, Shimizu T, Miyake T.

Prog Clin Biol Res. 1986;215:201-8. No abstract available.

PMID:
3088589

Supplemental Content

Loading ...
Support Center